非凡領越(00933.HK)盈喜:預期中期扭虧為盈至不少於8000萬港元
格隆匯8月2日丨非凡領越(00933.HK)公吿,根據初步評估集團截至2023年6月30日止6個月("2023年上半年")未經審核綜合管理賬目及目前可得資料,集團預計權益持有人應占溢利扭虧為盈,由截至2022年6月30日止6個月虧損3170萬港元轉為2023年上半年的溢利不少於8000萬港元。
集團表現的顯著改善主要得益於(i)由於由聯交所GEM轉至聯交所主板上市後的事實及情況變化,集團不再採用香港會計準則下的若干豁免;(ii)2022年7月初收購鞋履品牌Clarks,其收入及業績自此已合併至集團;(iii)集團多品牌鞋服業務分部下的若干品牌的虧損減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.